TrialJournal of atherosclerosis and thrombosis2025

Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial.

Wenli Dai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.